secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001104659-22-118973
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns
-------------------------------------------------------------------------------

- Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.
- Gross profit -$1.7M (Q3 2021: $1.8M); SG&A reduced to $2.2M from $3.4M on cost-cutting.
- Net loss widened to $13.8M from $1.7M; cash $11.2M vs $13.3M prior quarter.
- FDA approved label expansion for STENDRA (avanafil) for ED in men post-radical prostatectomy.
- Company shifts primary focus to over-the-counter access for STENDRA, citing improved shelf life.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/0001104659-22-118973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/tm2230572d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-118973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer